摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-4-{(S)-2-(2-Benzylsulfanyl-acetylamino)-3-[4-(di-tert-butoxy-phosphoryloxy)-phenyl]-propionylamino}-4-dipentylcarbamoyl-butyric acid tert-butyl ester | 205236-55-1

中文名称
——
中文别名
——
英文名称
(S)-4-{(S)-2-(2-Benzylsulfanyl-acetylamino)-3-[4-(di-tert-butoxy-phosphoryloxy)-phenyl]-propionylamino}-4-dipentylcarbamoyl-butyric acid tert-butyl ester
英文别名
tert-butyl (4S)-4-[[(2S)-2-[(2-benzylsulfanylacetyl)amino]-3-[4-[bis[(2-methylpropan-2-yl)oxy]phosphoryloxy]phenyl]propanoyl]amino]-5-(dipentylamino)-5-oxopentanoate
(S)-4-{(S)-2-(2-Benzylsulfanyl-acetylamino)-3-[4-(di-tert-butoxy-phosphoryloxy)-phenyl]-propionylamino}-4-dipentylcarbamoyl-butyric acid tert-butyl ester化学式
CAS
205236-55-1
化学式
C45H72N3O9PS
mdl
——
分子量
862.121
InChiKey
QRIVSYLVMSQMIK-UWXQCODUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    8.7
  • 重原子数:
    59
  • 可旋转键数:
    29
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.64
  • 拓扑面积:
    175
  • 氢给体数:
    2
  • 氢受体数:
    10

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (S)-4-{(S)-2-(2-Benzylsulfanyl-acetylamino)-3-[4-(di-tert-butoxy-phosphoryloxy)-phenyl]-propionylamino}-4-dipentylcarbamoyl-butyric acid tert-butyl ester三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 16.0h, 以44%的产率得到(S)-4-[(S)-2-(2-Benzylsulfanyl-acetylamino)-3-(4-phosphonooxy-phenyl)-propionylamino]-4-dipentylcarbamoyl-butyric acid
    参考文献:
    名称:
    Potent Dipeptide Inhibitors of the pp60c-src SH2 Domain
    摘要:
    The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60(c-src) SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)(2) (2) and the protein are established and form the basis for our structure-based drug design efforts. The effects of changes in both the C-terminal (11-27) and N-terminal (51-69) portions of the dipeptide are explored. Analogues with reduced overall charge (92-95) are also investigated. We demonstrate the feasibility of pairing structurally diverse subunits in a modest dipeptide framework with the goal of increasing the druglike attributes without sacrificing binding affinity.
    DOI:
    10.1021/jm970853a
  • 作为产物:
    参考文献:
    名称:
    Potent Dipeptide Inhibitors of the pp60c-src SH2 Domain
    摘要:
    The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60(c-src) SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)(2) (2) and the protein are established and form the basis for our structure-based drug design efforts. The effects of changes in both the C-terminal (11-27) and N-terminal (51-69) portions of the dipeptide are explored. Analogues with reduced overall charge (92-95) are also investigated. We demonstrate the feasibility of pairing structurally diverse subunits in a modest dipeptide framework with the goal of increasing the druglike attributes without sacrificing binding affinity.
    DOI:
    10.1021/jm970853a
点击查看最新优质反应信息

文献信息

  • Potent Dipeptide Inhibitors of the pp60<i><sup>c</sup></i><i><sup>-</sup></i><i><sup>src</sup></i> SH2 Domain
    作者:Gregory J. Pacofsky、Karen Lackey、Krystal J. Alligood、Judd Berman、Paul S. Charifson、Renae M. Crosby、George F. Dorsey,、Paul L. Feldman、Tona M. Gilmer、Conrad W. Hummel、Steven R. Jordan、Christopher Mohr、Lisa M. Shewchuk、Daniel D. Sternbach、Marc Rodriguez
    DOI:10.1021/jm970853a
    日期:1998.5.1
    The design, synthesis, and evaluation of dipeptide analogues as ligands for the pp60(c-src) SH2 domain are described. The critical binding interactions between Ac-Tyr-Glu-N(n-C5H11)(2) (2) and the protein are established and form the basis for our structure-based drug design efforts. The effects of changes in both the C-terminal (11-27) and N-terminal (51-69) portions of the dipeptide are explored. Analogues with reduced overall charge (92-95) are also investigated. We demonstrate the feasibility of pairing structurally diverse subunits in a modest dipeptide framework with the goal of increasing the druglike attributes without sacrificing binding affinity.
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物